English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

We appreciate the letter regarding our recently published CuVIC trial (Effect of Cholesterol Absorption Inhibitor Usage on Target Vessel Dysfunction After Coronary Stenting).1 As pointed, our notion that the improvement of coronary endothelial function in the ezetimibe plus statin treatment arm compared with statin alone arm might owe to the reductions in oxysterols was based on a post hoc analysis. In the analysis, we generated subgroups (n=62 each) by matching on-treatment low-density lipoprotein cholesterol (LDL-C) levels from the 2 treatment arms; therefore, it was important to assess baseline characteristics of the subgroups. Between the 2 on-treatment LDL-C–matched subgroups, there were no significant differences at the baseline, in background characteristics (sex, age, systolic blood pressure, and ejection fraction) and coronary risk factors (hypertension, diabetes mellitus, dyslipidemia, family …

arteriosclerosis, thrombosis, and vascular biology

Response by Takase and Matoba to Letter Regarding Article, “Ezetimibe in Combination With Statins Ameliorates Endothelial Dysfunction in Coronary Arteries After Stenting: The CuVIC Trial (Effect of Cholesterol Absorption Inhibitor Usage on Target Vessel Dysfunction After Coronary Stenting), a Multicenter Randomized Controlled Trial”